Business
Entera Bio Announces Full Year 2024 Financial Results and Provides Business Updates
JERUSALEM, March 28, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and proteins replacement therapies, today reported financial results and key business achievements for the year ended December 31, 2024. “2024 was a truly transformational year for Entera. We delivered key data read-outs and advanced each of our oral peptide PTH(1-34), GLP1/Glucagon and GLP2 tablet programs, significantly increased our stockholder value, and efficiently stre
About this update from Entera Bio Ltd.
[{"type":"image","alt":"Entera Bio Ltd.","displaySize":"","headline":null,"caption":"Entera Bio Ltd.","className":"","disableSlideshowImg":false,"size":{"original":{"width":164,"height":92,"url":"https://media.zenfs.com/en/globenewswire.com/ae9eba6049230107c762631bf8659d65"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/XGS._Ivm6nmvEHmx.FpICw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTExODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/ae9eba6049230107c762631bf8659d65","width":164,"height":92}},"lazy":false},{"type":"text","content":"JERUSALEM, March 28, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and proteins replacement therapies, today reported financial results and key business achievements for the year ended December 31, 2024.","length":264,"tagName":"p"},{"type":"text","content":"“2024 was a truly transformational year for Entera. We delivered key data read-outs and advanced each of our oral peptide PTH(1-34), GLP1/Glucagon and GLP2 tablet programs, significantly increased our stockholder value, and efficiently strengthened our balance sheet. To our core team with whom I started this journey in late 2022 as a board member, and to our rapidly expanding ecosystem of premier global advisors, I thank you for your commitment and dedication. To our existing and new shareholders, we are grateful for your belief and support of our thesis. To our collaborators, especially, the formidable team at OPKO Health, Inc., we are grateful for your partnership and the opportunity to expand our N-Tab™ platform to additional high value peptides,” said Miranda Toledano, Chief Executive Officer of Entera.","length":818,"tagName":"p"},{"type":"text","content":"“To our potential patient base for whom we are developing EB613: the majority of the estimated 200 million women with osteoporosis who wish to preserve their bone health, who remain underserved with current treatments and who have not been able to access a new therapy since 2019, our dedication to you is firm and unwavering. Osteoporosis is one of the foremost underserved health issues globally which disproportionally afflicts women. Most women experience menopause between the ages of 45 and 55 years. One in three women over age 50 will develop osteoporosis, and one in two of those women will develop an osteoporosis-related fracture. The ...